

CORTEX PHARMACEUTICALS INC/DE/  
Form 8-K/A  
July 10, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 9, 2015**

**CORTEX PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware                      1-16467              33-0303583**  
**(State or other jurisdiction (Commission (I.R.S Employer**  
**of incorporation)              File Number) Identification No.)**

**126 Valley Road, Suite C**

**07452**

**Glen Rock, New Jersey**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (201) 444-4947**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

*Explanatory Note*

On July 9, 2015, Cortex Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) that furnished, as Exhibit 99.1, a collection of slides that the Company intended to use in connection with its attendance at the National Angel-VC Summit & Growth Capital Forum being hosted at the Yale Club New York on July 9, 2015. Among other things, those slides referred to a clinical study of the compound dronabinol, which is being conducted by the University of Illinois (the “Study”). The Company attended the forum as scheduled, but noted that the estimated completion for the Study was incorrectly noted on slide 33 as 3Q2015, instead of the correct period, 2Q2016.

Accordingly, attached as Exhibit 99.1 to this Current Report on Form 8-K/A are revised slides (the “Revised Slides”) that include the corrected date on slide 33. The full slide deck, with the updated slide 33, will also be available on the Company’s web-site.

The remainder of the information provided with the Original Report remains unchanged.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

A list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 10, 2015 CORTEX PHARMACEUTICALS, INC.  
(Registrant)

By: */s/ Arnold S. Lippa*  
Arnold S. Lippa  
President and Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	Revised Slides amending certain slides furnished as Exhibit 99.1 to the Company's Current Report on Form 8-K filed July 9, 2015*

\* Furnished herewith

